Overview
| Trade Names: | DEA No. 1605; Dimagrir; Magrilon; Mazanor; Mazildene; Mazindol [USAN:BAN:INN]; Mazindolum [INN-Latin]; Sanorex; Terenac; Teronac |
|---|---|
| PharmGKB Accession Id: | PA450326 |
Description
Tricyclic anorexigenic agent unrelated to and less toxic than amphetamine, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter. PubChem (source: Drug Bank)
Indication
Used in short-term (a few weeks) treatment of exogenous obesity in conjunction with a regimen of weight reduction based on caloric restriction, exercise, and behavior modification in patients with a body mass index of 30 kg of body weight per height in meters squared (kg/m<sup>2</sup>) or in patients with a body mass index of 27 kg/m<sup>2</sup> in the presence of risk factors such as hypertension, diabetes, or hyperlipidemia. (source: Drug Bank)
ATC Therapeutic Category
- A08AA:Centrally acting antiobesity products
Pharmacology, Interactions, and Contraindications
Mechanism Of Action
Although the mechanism of action of the sympathomimetics in the treatment of obesity is not fully known, these medications have pharmacological effects similar to those of amphetamines. Unlike other sympathomimetic appetite suppressants such as phentermine, mazindol is thought to inhibit the reuptake of norepinephrine rather than to cause its release. (source: Drug Bank)
Pharmacology
Mazindol is a sympathomimetic amine, which is similar to an amphetamine. Mazindol stimulates the central nervous system (nerves and brain), which increases your heart rate and blood pressure and decreases your appetite. Sympathomimetic appetite suppressants are used in the short-term treatment of obesity. Their appetite-reducing effect tends to decrease after a few weeks. Because of this, these medicines are useful only during the first few weeks of a weight-loss program. (source: Drug Bank)
Food Interactions
If product causes GI problems, it can be taken during meals.
May be taken without regard to meals, but preferably 1 hour before a meal.
(source:
Drug Bank)
Absorption, Distribution, Metabolism, Elimination & Toxicity
Biotransformation
Hepatic. (source: Drug Bank)
Toxicity
Symptoms of a mazindol overdose include restlessness, tremor, rapid breathing, confusion, hallucinations, panic, aggressiveness, nausea, vomiting, diarrhea, an irregular heartbeat, and seizures. (source: Drug Bank)
Isomeric SMILES Code:
C1C[N@]2C(=N1)C3=CC=CC=C3[C@]2(C4=CC=C(C=C4)Cl)O (source: Drug Bank)
A list of non-curated publications that mention this drug along with other genes is available.
Drug Targets
| Gene | Description | |
|---|---|---|
| SLC6A3 |
|
(source: Drug Bank) |
| SLC6A2 |
|
(source: Drug Bank) |
A list of non-curated publications that mention this drug along with other drugs is available.
Drug Interactions
| Drug | Description | |
|---|---|---|
| chlorpromazine |
|
Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank) |
| ethopropazine |
|
Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank) |
| fluoxetine |
|
Risk of serotoninergic syndrome (source: Drug Bank) |
| fluphenazine |
|
Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank) |
| fluvoxamine |
|
Risk of serotoninergic syndrome (source: Drug Bank) |
| guanethidine |
|
The agent decreases the effect of guanethidine (source: Drug Bank) |
| isocarboxazid |
|
Possible hypertensive crisis (source: Drug Bank) |
| mesoridazine |
|
Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank) |
| paroxetine |
|
Risk of serotoninergic syndrome (source: Drug Bank) |
| perphenazine |
|
Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank) |
| phenelzine |
|
Possible hypertensive crisis (source: Drug Bank) |
| prochlorperazine |
|
Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank) |
| promazine |
|
Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank) |
| promethazine |
|
Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank) |
| thioridazine |
|
Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank) |
| tranylcypromine |
|
Possible hypertensive crisis (source: Drug Bank) |
| trifluoperazine |
|
Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank) |
| triflupromazine |
|
Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank) |
| venlafaxine |
|
Risk of serotoninergic syndrome (source: Drug Bank) |
Non-Curated Information
A list of non-curated publications that mention this drug along with other diseases is available.
LinkOuts
Common Searches
Search PubMed
Search Medline Plus
Search PubChem
Search CTD
Non-Curated Publications
A list of non-curated publications that mention this drug is available.
